Investigational drug · Phase 3
rhGM-CSF
Also called: Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor, Molgramostim Open-label
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Autoimmune Pulmonary Alveolar Proteinosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
35
Any phase or sponsor naming "rhGM-CSF"
First trial start
2021
May 19, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rhGM-CSF", any sponsor or status.
- Phase 221
Conditions studied
As listed on its trial records.
- Autoimmune Pulmonary Alveolar Proteinosis
Largest trials
Live from ClinicalTrials.gov: studies naming "rhGM-CSF" as an intervention, largest first.
- Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness BurnPivotal-lookingCompleted
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT01785784 · 2,510 participants · Start Nov 2010 · Primary completion Apr 2012
Drug: rhGM-CSF Gel · For: Deep Partial Thickness Burn
- Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCTPivotal-lookingCompleted
Xiamen Amoytop Biotech Co., Ltd.Industry
NCT01232504 · 206 participants · Start Sep 2009 · Primary completion Mar 2013
Drug: rhGM-CSF group; rhG-CSF+rhGM-CSF group and 1 more · For: Mycoses
Sites: Nanning, China; Zhengzhou, China; Wuhan, China · 5 sites in all
- Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Pivotal-lookingActive, not recruiting
Savara Inc.Industry
NCT04544293 · 164 participants · Start May 19, 2021 · Primary completion Nov 30, 2023
Drug: Molgramostim; Placebo and 1 more · For: Autoimmune Pulmonary Alveolar Proteinosis
Sites: Little Rock, Arkansas; Los Angeles, California; Denver, Colorado · 54 sites in all
- Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral MucositisPivotal-lookingStatus unknown
Wei LUOAcademic, hospital or other
NCT01806272 · 160 participants (planned) · Start Mar 2013 · Primary completion Jun 2014
Drug: rhGM-CSF; Compound Vitamin B12 · For: Nasopharyngeal Cancers
Sites: Guangzhou, China
- Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar ProteinosisPivotal-lookingCompleted
Savara Inc.Industry
NCT02702180 · 139 participants · Start Mar 21, 2016 · Primary completion Apr 19, 2019
Drug: Molgramostim; Placebo · For: Autoimmune Pulmonary Alveolar Proteinosis
Sites: Los Angeles, California; Gainesville, Florida; Cincinnati, Ohio · 30 sites in all
- Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma PatientsPivotal-lookingStatus unknown
Laboratorio Pablo Cassara S.R.L.Industry
NCT01729663 · 108 participants (planned) · Start Apr 2009 · Primary completion Dec 2018
Drug: CSF470 vaccine, BCG, Molgramostim; interferon alpha 2b · For: Cutaneous Melanoma
Sites: Buenos Aires, Argentina
University of Wisconsin, MadisonAcademic, hospital or other
NCT01341652 · 99 participants · Start May 23, 2011 · Primary completion Jun 30, 2020
Drug: pTVG-HP; rhGM-CSF · For: Prostate Cancer
Sites: San Francisco, California; Baltimore, Maryland; Madison, Wisconsin
Tongji HospitalAcademic, hospital or other
NCT06552598 · 97 participants (planned) · Start Apr 1, 2024 · Primary completion Apr 1, 2028
Drug: KD01(the recombinant oncolytic adenovirus) · For: Cervical Cancer; Gynecologic Malignancies; Endometrial Cancer
Sites: Wuhan, China
University of Wisconsin, MadisonAcademic, hospital or other
NCT02499835 · 66 participants · Start Jul 1, 2015 · Primary completion Aug 9, 2021
Drug: Pembrolizumab; pTVG-HP Plasmid DNA Vaccine · For: Hormone-Resistant Prostate Cancer; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues and 4 more
Sites: Madison, Wisconsin
- Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial TumorsStatus unknown
Shanghai Cancer Hospital, ChinaAcademic, hospital or other
NCT04517539 · 65 participants (planned) · Start Dec 1, 2020 · Primary completion Dec 1, 2022
Drug: rhGM-CSF,Peginterferon alfa-b2,radiation · For: Thymic Epithelial Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Systematic engineering of Pichia pastoris for high-level production of recombinant human granulocyte-macrophage colony-stimulating factor.
Cheng Z, Gong K, Song Y, et al. · Bioresour Technol 2026
- The Therapeutic Pipeline: Future Treatments and Precision Medicine.
Franco G, Peri G, Ugonino-Gralino A, et al. · Semin Respir Crit Care Med 2026
- The changing landscape of autoimmune pulmonary alveolar proteinosis.
Jouneau S, McCarthy C · Respir Med Res 2026
- Molgramostim improves exercise distance and duration in autoimmune pulmonary alveolar proteinosis: exploratory IMPALA-2 trial data.
McCarthy C, Bonella F, Inoue Y, et al. · Ann Am Thorac Soc 2026
- Inhaled granulocyte-macrophage colony-stimulating factor (molgramostim) as host-directed therapy for pneumonia-related acute respiratory distress syndrome: a multicentre, randomised, placebo-controlled phase 2a trial (GI-HOPE).
Herold S, Welte T, Zacharowski K, et al. · ERJ Open Res 2026
- Effectiveness of a rhGM-CSF-Containing Gel on Promoting Wound Healing After 1927-nm Fractional Thulium Fiber Laser Treatment of Atrophic Acne Scars: A Prospective, Randomized, Split-Face, and Evaluator-Blinded Clinical Trial.
Ma Y, Qi C, Liu J, et al. · Aesthetic Plast Surg 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.